Hints and tips:
...Rivals AstraZeneca, Johnson & Johnson, Russia’s Sputnik V and new entrants such as Novavax make up the remainder of the market, which is forecast to double in value to $124bn next year....
...Players of Fortnite, developed by Epic, were able to purchase an in-game currency known as “V-bucks” online, but these credits would not show up when playing on the iPhone....
...The AU will pay $6.75 a dose for the BioNTech/Pfizer vaccine and $10 for Johnson & Johnson’s, a single-dose product....
...After such strong reads from the first two releases (three if we count Russia’s Sputnik V), the disappointing AZN figures were perhaps bound to prompt downward pressure on the company’s shares....
...In August, Russia became the first country to approve a Covid-19 vaccine — named Sputnik V — for civilian use, but western experts cast doubt on its efficacy and safety....
...A planned takeover of Allergan by US drugmaker Pfizer in 2015 fell through a year later when Barack Obama’s administration took steps to scupper a deal which was designed to help Pfizer escape paying US...
...For Mr Gonzalez, whose shares plunged 15 per cent after the deal was announced, the threat to AbbVie had been clear for years....
...It was followed by Pfizer’s $11.4bn purchase of oncology specialist Array BioPharma and Eli Lilly’s $8bn buyout of Loxo Oncology....
...A star-studded jury featuring Alejandro González Iñárritu, Elle Fanning and Yorgos Lanthimos is ready to ascend the red-carpeted stairway of the Palais des Festivals....
...Asked whether AbbVie makes a profit on drugs that it sells in Germany and France, Mr González said it does....
...The Stemcentrx acquisition marks a second big oncology deal for Rick Gonzalez, AbbVie chief executive, in just over a year....
...For Rick González, AbbVie chief executive, it is the second big deal in oncology in just over a year....
...Pfizer, too, was on the prowl after failing to acquire the UK’s AstraZeneca last year....
...So far this year, Valeant has acquired gastrointestinal drugmaker Salix for $14.5bn, Pfizer bought Hospira for $17bn and Shire picked up NPS Pharma for $5.2bn....
...Richard Gonzalez, chief executive of AbbVie, described the takeover battle as “one of the most competitive I’ve ever seen”....
...Pfizer’s failed $110bn offer for AstraZeneca also showed that mergers among the biggest groups cannot be ruled out altogether....
...The addition of Pharmacyclics’ talented and innovative team will add enormous value to AbbVie,” said Richard A Gonzalez, AbbVie’s chairman and chief executive....
...“We have met with the majority of shareholders, they understand the strategic rational,” Mr Gonzalez told the FT....
...AbbVie boss Richard Gonzalez has avoided the same mistake in attempting a bear hug of his own. There is thus scope for him to meet Shire in the middle, if the board moots £60 per share....
...AbbVie, the US drugmaker, this week sought to quash doubt over its £32bn takeover of UK-listed Shire, when Richard Gonzalez, chief executive, told employees he was “more energised than ever about our two...
...Shire is the second FTSE 100 drugmaker to face an unwanted approach from a US rival this year after Pfizer’s abortive £69bn offer for AstraZeneca....
...However, AbbVie highlighted the 58 per cent premium over the price in mid-April, before news of Pfizer’s interest in AstraZeneca caused takeover speculation surrounding Shire to intensify....
...Mr Gonzalez declined to rule out a higher offer or the possibility of taking the bid direct to shareholders if Shire’s board refused to negotiate....
...Perhaps Richard Gonzalez did not make it to page 190 of the Takeover Code....
International Edition